---
title: "12 Health Care Stocks Moving In Tuesday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290610705.md"
description: "In Tuesday's after-market session, several healthcare stocks saw significant movement. Gainers included Quoin Pharmaceuticals (up 40.3%), Mobile-health Network (up 35.71%), and ALPS Group (up 26.27%). Conversely, losers featured Aditxt (down 8.2%), Vivos Therapeutics (down 7.53%), and Spyre Therapeutics (down 7.53%). The report highlights specific price changes and market capitalizations for these listed companies."
datetime: "2026-06-23T21:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290610705.md)
  - [en](https://longbridge.com/en/news/290610705.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290610705.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Tuesday's After-Market Session

### Gainers

-   **Quoin Pharmaceuticals** (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
-   **Mobile-health Network** (NASDAQ:MNDR) shares increased by 35.71% to $0.77. The company's market cap stands at $4.1 million.
-   **ALPS Group** (NASDAQ:ALPS) shares increased by 26.27% to $0.79. The company's market cap stands at $112.4 million.
-   **Catheter Precision** (AMEX:VTAK) shares moved upwards by 17.39% to $1.08. The company's market cap stands at $2.3 million.
-   **Tempest Therapeutics** (NASDAQ:TPST) stock moved upwards by 13.94% to $1.43. The company's market cap stands at $18.5 million.
-   **Exicure** (NASDAQ:XCUR) shares increased by 8.79% to $2.97. The company's market cap stands at $17.4 million.

### Losers

-   **Aditxt** (NASDAQ:ADTX) shares declined by 8.2% to $0.04 during Tuesday's after-market session.
-   **Vivos Therapeutics** (NASDAQ:VVOS) shares decreased by 7.53% to $0.43. The market value of their outstanding shares is at $5.5 million.
-   **Spyre Therapeutics** (NASDAQ:SYRE) stock fell 7.53% to $89.75. The market value of their outstanding shares is at $8.6 billion.
-   **Silexion Therapeutics** (NASDAQ:SLXN) shares decreased by 7.39% to $2.51. The market value of their outstanding shares is at $2.8 million.
-   **Galmed Pharmaceuticals** (NASDAQ:GLMD) stock fell 6.68% to $0.53. The market value of their outstanding shares is at $4.3 million.
-   **Onconetix** (NASDAQ:ONCO) stock declined by 5.61% to $1.01. The company's market cap stands at $3.5 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md)
- [VVOS.US](https://longbridge.com/en/quote/VVOS.US.md)
- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)
- [QNRX.US](https://longbridge.com/en/quote/QNRX.US.md)
- [MNDR.US](https://longbridge.com/en/quote/MNDR.US.md)
- [ALPS.US](https://longbridge.com/en/quote/ALPS.US.md)
- [VTAK.US](https://longbridge.com/en/quote/VTAK.US.md)
- [TPST.US](https://longbridge.com/en/quote/TPST.US.md)
- [XCUR.US](https://longbridge.com/en/quote/XCUR.US.md)
- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [GLMD.US](https://longbridge.com/en/quote/GLMD.US.md)
- [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md)
- [74907L409.US](https://longbridge.com/en/quote/74907L409.US.md)
- [ALPWF.US](https://longbridge.com/en/quote/ALPWF.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome | QNRX Stock News](https://longbridge.com/en/news/297303800.md)
- [Quoin reports positive interim Phase 2/3 data for QRX003 in Netherton syndrome trial](https://longbridge.com/en/news/297303303.md)
- [Spyre Therapeutics reports Phase 2 SKYWAY RA data for SPY072 shows statistically significant benefit vs placebo](https://longbridge.com/en/news/297018031.md)
- [Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 | SYRE Stock News](https://longbridge.com/en/news/296951295.md)
- [Quoin Pharma prices unregistered $50 million private placement at $4.88 per ADS](https://longbridge.com/en/news/297303248.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**